Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Wednesday's pitch from out of nowhere by the

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
powerwalker Member Profile
 
Followed By 12
Posts 3,493
Boards Moderated 0
Alias Born 06/17/09
160x600 placeholder
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patie... GlobeNewswire Inc. - 9/16/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 5:11:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/13/2019 5:07:24 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/13/2019 5:02:44 PM
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019 GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
powerwalker   Friday, 07/05/19 06:56:12 AM
Re: None
Post # of 232196 
Wednesday's pitch from out of nowhere by the TGD would have made Sal the Barber proud with its "chin music."

FYI - Anavex had 48.17 million shares o/s at 3/31; on 7/3, that number had increased to 51.66, an increase ~3.5 million. This probably brought in ~$12 million, most, if not all, in the 3rd fiscal quarter.

As to the number of shares that the shelf could cover, let’s use some logic and estimates: 9-10 million shares are committed for stock options, awards for employees; add another 5 million for future grants. This adds up to ~67 Million shares. If the Cantor and LPC deals as each is today are cancelled, Anavex has ~33 million shares left to reach the 100 million authorized share limit. If Anavex wants to leave a cushion of 20 million shares before it goes to the shareholders for an increase in those authorized shares, that allows ~13 million to issue under the shelf.

Therefore, give or take a few hundred thousand shares, it provides the $250 million at approximately $20/share. If the Consortium, which I believe has seen a portion of the various trials’ results, [i.e., “Why are you doing Rett/PDD in Australia?”], were the interested party, the seven other companies in it, could buy proportionally about 1.8 million shares for $36 million each with the understanding that each has first dibs on one of the Anavex’s pipeline drugs to assist in trials and, if successful, production, marketing and distribution.

As to Wednesday’s wild discussions about HH, IMO, HH had to leave because negotiations with a company (or the Consortium), and not necessarily Eisai, had moved beyond the first date. Though only a SAB member, HH's ties to Anavex would have given him information that should not be in the hands of someone whose loyalties would be divided.

As to the points made that the shelf is a desperate measure by Dr. M and Anavex to raise funds now because the PDD and/or Rett results are failing, the Aussie government would NOT allow for Anavex to commence trials there if the numbers were not encouraging. IMO, this confidence in Anavex by the Aussies is indicative of positive results on both fronts.

P..S. On preferred stock, I don't believe it was presented as a convertible offering. To be that, shareholders need to approve that.

ANAVEX NOW ... MONO-STYLE ... RWEm for Life!!!

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist